Greystone Program

Greystone Program

In the 2025 National Directory of Mental Health Treatment Facilities. Intake 215-880-2154.

Type of Care

Mental health treatment (MH); Treatment for co-occurring substance use plus either serious mental illness (SMI) in adults and/or serious emotional disturbance (SED) in children (SUMH)

Service Setting

Residential/24-hour residential (RES)

Pharmacotherapies

Fluphenazine (FLUPH); Haloperidol (HALOP); Aripiprazole (ARIPI); Clozapine (CLOZA); Olanzapine (OLANZ); Quetiapine (QUETI); Risperidone (RISPE); Nicotine replacement (NRT); Non-nicotine smoking/tobacco cessation (NSC); Antipsychotics used in treatment of SMI (ANTPYCH)

Treatment Approaches

Activity therapy (AT); Group therapy (GT); Abnormal involuntary movement scale (AIMS)

Facility Operation (e.g., Private, Public)

Private for-profit organization (PVTP)

Payment/Insurance/Funding Accepted

Cash or self-payment (CASH)

Special Programs/Groups Offered

Seniors or older adults (SEN); Clients who have experienced trauma (TRMA); Persons experiencing first-episode psychosis (FEP)

Assessment/Pre-treatment

Screening for tobacco use (STU)

Testing

Metabolic syndrome monitoring (MST); Laboratory testing (LABT)

Education and Counseling Services

Smoking/vaping/tobacco cessation counseling (TCC)

Facility Smoking Policy

Smoking permitted in designated area (SMPD)

Age Groups Accepted

Seniors (SNR)

Facility Vaping Policy

Vaping permitted in designated area (VPPD)

Ancillary Services

Chronic disease/illness management (CDM); Diet and exercise counseling (DEC); Family psychoeducation (FPSY); Illness management and recovery (IMR); Psychosocial rehabilitation services (PRS); Suicide prevention services (SPS)